Medications and Therapies
Drugs acting on or through oligodendrocytes: approved MS therapies, remyelination candidates, and investigational agents.
Anti-CD20 B-cell depletion reduces relapse rate and new lesions in relapsing MS. Oligodendrocyte protection is indirect, by removing the immune attack.
The trial behind the first approval for primary progressive MS, a form with no previous disease-modifying option.
Anti-VLA-4 blocks lymphocyte entry to the CNS. Carries PML risk, which is JC virus replicating in oligodendrocytes themselves.
An antimuscarinic antihistamine repurposed as a differentiation promoter. In this crossover trial it shortened visual evoked potential latency in chronic optic neuropathy, the first remyelination signal from a drug in humans.
S1P receptor modulator approved for secondary progressive MS. S1P5 is expressed on oligodendrocytes, so a direct effect is plausible alongside the immune one.
High-dose biotin as a cofactor for the carboxylases in myelin fatty acid synthesis. Later phase III work did not confirm the benefit; not approved.
High-throughput screen identifying benztropine and other antimuscarinics as OPC differentiation promoters. The origin of the clemastine hypothesis.
RXR gamma is required for OPC differentiation; agonists accelerate remyelination in aged rodents. The retinoid pathway as a repair target.
Stabilising Axin2 dampens Wnt signalling in OPCs and accelerates their maturation, linking a developmental pathway to a repair target.
Mouse, preclinical. Fibronectin piling up in lesions traps OPCs short of repair; inhibiting it systemically restored remyelination and clinical remission.
Mouse ALS model. A brain-penetrant GPR17 agonist restored oligodendrocyte maturation, extended survival and improved motor function in females, with no benefit in males.